Cardioprotection by opening of the K(ATP) unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil

European Heart Journal

Volumn 20, Issue 1, 1999, Pages 51-57

  Patel, D J ^a   Purcell, H J ^a   Fox, K M ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Ischaemic preconditioning; Nicorandil; Unstable angine

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; NICORANDIL; PLACEBO; POTASSIUM CHANNEL; TROPONIN;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TACHYCARDIA; THORAX PAIN;

ADENOSINE TRIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANGINA, UNSTABLE; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HEART; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NICORANDIL; POTASSIUM CHANNELS; RETROSPECTIVE STUDIES; SAFETY; TREATMENT OUTCOME;

EID: 0032949661     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1354     Document Type: Article

References (15)

1. Neuhaus, KL, Coronary thrombosis - defining the goals, improving the outcome.
2. Braunwald, E, Mark, DB, Jones, RH, Unstable Angina: Diagnosis and management.
3. Anderson HV, Cannon CP, Stone PH. One-year results of the thrombolysis in myocardial infarction (TIMI) IIIB clinical trial. J Am Coll Cardiol. 26:1995;1643-1650.
4. Grambow DW, Topol EJ. Effect of maximal medical therapy on refractoriness of unstable angina pectoris. Am J Cardiol. 70:1992;577-581.
5. Purcell H, Patel D, Mulcahy D, Fox KM. Nicorandil. Cardiovascular drug therapy. 1996;WB Saunders, Philadelphia. p. 1638-45.
6. Akai K, Wang Y, Sato K. Vasodilatory effect of nicorandil on coronary arterial microvessels: Its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol. 26:1995;541-547.
7. Yellon DM, Baxter GF, Marber MS. Angina reassessed; pain or protector? Lancet. 347:1996;1159-1162.
8. Krumenacker M, Roland EO. Clinical profile of nicorandil: An overview of its haemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol. 20:1992;S93-S102.
9. Frampton J, Buckley M, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs. 44:1992;625-655.
10. Kato K, Iinuma H, Hirosawa K. Clinical evaluation of intravenous SG-75 in treatment of unstable angina - a multicentre double-blind comparative study with intravenous ISDN. Rinsho Iyaku. 7:1991;2031-2054.
11. Fukami K, Haze K, Sumiyoshi T. Beneficial effects of intravenous nicorandil in refractory unstable angina. Eur Heart J. 9:1988;64.
12. Klein HH, Pich S, Lindert-Heimberg S, Schade-Brittinger C, Maisch B, Nebendahl K. Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts. Eur Heart J. 16:1995;603-609.
13. +. Circ Res. 77:1995;1030-1035.
14. Billman GE. Role of the ATP sensitive potassium channel in extracellular potassium accumulation and cardiac arrhythmias during myocardial ischaemia. Cardiovasc Res. 28:1994;762-769.
15. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning the ischaemic myocardium involve cyclo-oxygenase products. Cardiovasc Res. 24:1990;1020-1023.